University Meningitis Outbreak Highlights Critical Vaccine Policy Gap
A tragic meningitis outbreak at the University of Kent has resulted in two student fatalities and twenty individuals receiving medical treatment, starkly illuminating a systemic failure in Britain's vaccination strategy that has persisted for over a decade. The affected students represent a generation that has never received routine immunisation against the specific bacterial strain responsible for the outbreak, meningococcal group B.
A Vaccine Existed But Was Not Offered
This gap in protection is not due to a lack of available medical technology. The Bexsero vaccine, which effectively guards against meningococcal group B disease, has been commercially available since 2013. The United Kingdom made global public health history in September 2015 by becoming the first nation to incorporate this vaccine into its national childhood immunisation schedule. However, this landmark decision came with a critical and, as now evidenced, fatal limitation: the programme was exclusively offered to infants.
Every student currently enrolled in higher education was born before the July 2015 implementation date, automatically excluding them from receiving the jab through the National Health Service. No subsequent catch-up initiative was ever established, leaving an entire decade's worth of university entrants without routine defence against the most prevalent form of bacterial meningitis.
The Economic Calculus Behind the Policy
The government's advisory body, the Joint Committee on Vaccination and Immunisation (JCVI), made the deliberate choice not to extend vaccination beyond infancy. This decision stemmed from a complex evaluation where the perceived benefits for older children and teenagers did not meet the stringent economic threshold required to justify the programme's cost to the taxpayer.
Unlike many vaccines that confer herd immunity by reducing overall transmission within a population, Bexsero operates differently. It provides robust individual protection to the recipient but does not significantly reduce the carriage of the bacteria in people's throats or its spread to others. Consequently, vaccinating a baby protects that child alone, without creating a protective ripple effect throughout the community. The JCVI concluded that, without this broader societal benefit, the justification for a wider rollout was insufficient.
University Life: A Perfect Storm for Transmission
This economic calculation, however, failed to adequately account for the uniquely high-risk environment of university campuses. Meningococcal bacteria thrive on close contact—activities like kissing, sharing beverages, and congregating in crowded lecture halls or nightclubs are commonplace during freshers' week and beyond.
Scientific research underscores this acute danger. A UK study monitoring students found the rate of bacterial carriage in throats skyrocketed from under 7% on their first day to over 23% by day four of university life. In catered halls of residence, this figure climbed to 34% by December. Comparative American data reveals that first-year undergraduates face a risk of contracting meningococcal B disease nearly twelve times higher than non-student peers of the same age, with residence in university halls amplifying the threat even further.
The Private Paywall to Protection
For parents aware of these risks, a private route to vaccination existed, but it came at a significant financial cost. A full immunisation course for anyone over the age of eleven requires two doses of Bexsero, typically costing around £110 per dose at most pharmacies, totalling £220 or more. Some private clinics charge substantially higher fees.
This created a stark health inequality, where a child's protection became contingent on their family's wealth. The Kent outbreak has brutally exposed this divide, with bookings for private meningitis B vaccinations at retailers like Superdrug surging to sixty-five times their normal level in the aftermath—a rush dominated by those who can afford the expense.
Reassessing the Long-Term Costs
While vaccine policy inherently involves difficult resource allocations, the economic rationale for restricting the programme to infants has grown increasingly questionable. A 2021 re-analysis published in Value in Health journal argued that incorporating the full burden of disease—including long-term care needs, loss of future earnings, and impacts on families—brings the cost per year of healthy life gained below the NHS's standard approval threshold.
The immediate financial savings from not vaccinating teenagers may be generating far greater long-term societal and economic costs. Furthermore, the emergency response to the Kent outbreak itself carries a heavy price tag, involving contacting over 30,000 people in the Canterbury area, distributing thousands of antibiotic doses, and launching a targeted vaccination campaign for at-risk students.
A Call for Policy Review
In response to the crisis, Health Secretary Wes Streeting has committed to asking the JCVI to re-examine eligibility for meningitis vaccines. This review is widely seen as both necessary and long overdue.
The first cohort of babies vaccinated under the 2015 programme will not reach university age until 2033. This means that, unless policy is urgently revised, every new student arriving at freshers' week for the next several years will continue to enter this high-risk environment without the routine protection that could prevent future tragedies. The events at Kent serve as a sombre reminder that public health decisions have profound and lasting human consequences.
